AKRO is expected to report earnings to rise 4.94% to -85 cents per share on November 13
Q3'24
Est.
$-0.85
Q2'24
Beat
by $0.02
Q1'24
Est.
$-0.90
Q4'23
Missed
by $0.16
Q3'23
Missed
by $0.01
The last earnings report on August 09 showed earnings per share of -81 cents, beating the estimate of -82 cents. With 281.86K shares outstanding, the current market capitalization sits at 1.99B.
a biotechnology company, which specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.